N/A (device / behavioral)Not yet recruitingNCT07517770
AI bolus priming added to AIDANET
What this study tests
Study of artificial-intelligence bolus priming layered onto an existing fully automated AIDANET algorithm.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-04-08.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults with T1D for at least 1 year currently using AID, with an emergency support person nearby and willingness to use study devices. Recent severe hypoglycemia or DKA and current SGLT inhibitor use are among exclusions. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Time in Range (TIR) 70-180 mg/dL for 2-week free-living at home periods on AIDANET vs AIDANET AI.
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT07517770: AI bolus priming added to AIDANET · Trial registry